#1 Clinical Trials Search in Europe

Cetirizine Dihydrochloride

This article examines the use of Cetirizine Dihydrochloride, a common antihistamine, in various clinical trials. These studies investigate different formulations, dosages, and applications of cetirizine for treating allergic conditions, particularly allergic rhinitis. The trials explore bioequivalence between different formulations, efficacy compared to other antihistamines, and the drug’s performance under various conditions.

Table of Contents

What is Cetirizine Dihydrochloride?

Cetirizine Dihydrochloride is a medication commonly used to treat allergy symptoms. It belongs to a class of drugs called antihistamines, which work by blocking the effects of histamine, a substance your body produces during an allergic reaction[1]. Cetirizine is available under various brand names, including Zyrtec® and Reactine®[4].

What Conditions Does Cetirizine Treat?

Cetirizine is primarily used to treat the following conditions:

  • Allergic Rhinitis: This includes both seasonal allergies (hay fever) and year-round allergies. Symptoms may include sneezing, runny nose, and itchy eyes[1][2].
  • Other Allergic Conditions: Cetirizine can also help with other allergic reactions, such as skin allergies[4].

Available Formulations

Cetirizine comes in several different formulations to suit various patient needs:

  • Tablets: Standard immediate-release tablets, typically 10 mg[5].
  • Chewable Tablets: These can be chewed before swallowing, which may be easier for some patients to take[3].
  • Orodispersible Tablets (ODT): These tablets dissolve quickly in the mouth without needing water[4].
  • Nasal Spray: A newer formulation that delivers the medication directly into the nose[1].

How Cetirizine Works

Cetirizine is a second-generation antihistamine. It works by blocking histamine receptors in the body, which helps to reduce allergy symptoms. Unlike some older antihistamines, cetirizine is less likely to cause drowsiness, making it a popular choice for daytime use[1].

Dosage and Administration

The typical dose of cetirizine for adults and children 12 years and older is 10 mg once daily. However, the exact dosage may vary depending on the specific formulation and individual patient needs. Always follow your healthcare provider’s instructions or the package directions[3][5].

Some important points about taking cetirizine:

  • It can be taken with or without food[3].
  • If using the orodispersible tablets, they can be taken with or without water[4].
  • Chewable tablets should be chewed thoroughly before swallowing[3].

Effectiveness of Cetirizine

Research has shown that cetirizine is effective in reducing allergy symptoms. In clinical trials, it has been found to improve quality of life for people with allergic rhinitis and reduce the need for additional “rescue” medications[2].

The onset of action for cetirizine can be relatively quick. Some studies have looked at its effectiveness within hours of taking the medication[6].

Potential Side Effects

While cetirizine is generally well-tolerated, like all medications, it can cause side effects in some people. Common side effects may include:

  • Drowsiness (although less common than with older antihistamines)
  • Dry mouth
  • Fatigue
  • Headache

In studies, researchers have also looked at “local tolerance” when using cetirizine nasal sprays, which refers to how well the nose tolerates the medication[1].

Ongoing Research

Researchers continue to study cetirizine to better understand its effects and develop new formulations. Some areas of ongoing research include:

  • New Formulations: Studies are looking at different ways to deliver cetirizine, such as nasal sprays and orodispersible tablets, to improve effectiveness and patient convenience[1][4].
  • Bioequivalence Studies: These studies compare different formulations of cetirizine to ensure they work the same way in the body[3][4].
  • Comparison with Other Treatments: Some studies compare cetirizine to other allergy treatments, including other antihistamines and alternative therapies like acupuncture[2][6].
Aspect Details
Drug Formulations Chewable tablets, orodispersible tablets (ODT), immediate-release tablets, nasal sprays
Main Conditions Studied Allergic rhinitis, seasonal allergies
Key Measures Bioequivalence, plasma concentration, symptom scores, patient tolerability
Comparison Studies Different cetirizine formulations, cetirizine vs. levocetirizine
Special Considerations Food effects, ease of swallowing, taste perception
Study Designs Randomized, crossover, bioequivalence studies

FAQ

  • What is Cetirizine Dihydrochloride used for in these clinical trials? Cetirizine Dihydrochloride is primarily used to treat allergic conditions, especially allergic rhinitis (hay fever). The trials investigate its efficacy in reducing allergy symptoms and compare different formulations of the drug.
  • What types of cetirizine formulations are being studied? The trials examine various formulations of cetirizine, including chewable tablets, orodispersible tablets (ODT), immediate-release tablets, and nasal sprays. Some studies compare these formulations to determine bioequivalence and patient preference.
  • How is the effectiveness of cetirizine measured in these trials? Effectiveness is measured through various methods, including symptom scores (like the Rhinitis Quality of Life Questionnaire), plasma concentration levels, and bioavailability measures such as maximum observed plasma concentration (Cmax) and area under the curve (AUC).
  • Are there any comparisons between cetirizine and other antihistamines? Yes, some trials compare cetirizine to other antihistamines. For example, one study compares the efficacy of levocetirizine and cetirizine in reducing symptoms of seasonal allergic rhinitis in ragweed-sensitive subjects.
  • What are some of the key findings from these clinical trials? The trials provide insights into the bioequivalence of different cetirizine formulations, the drug's effectiveness in treating allergic rhinitis, and its performance under various conditions (e.g., with or without food). Some studies also explore patient preferences and the tolerability of different formulations.

Ongoing Clinical Trials on Cetirizine Dihydrochloride

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study on the Safety of Eight Treg and Drug Combination for Patients with Chronic Kidney Failure Undergoing Transplant from a Living Donor

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of GNT0003 and imlifidase in adults with Crigler-Najjar syndrome who require daily phototherapy and have pre-existing AAV8 antibodies

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

    Recruiting

    1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

  • Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

    Recruiting

    1 1 1
    Investigated drugs:
    France The Netherlands Spain

  • Study of rituximab for reducing pain in patients with fibromyalgia caused by autoantibodies

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on the Safety and Effectiveness of PLX-PAD Cells for Patients with Mild to Moderate Knee Osteoarthritis

    Not yet recruiting

    1 1
    Investigated drugs:
    Germany

  • Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8

  • Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Croatia Denmark France Germany Greece +6

Glossary

  • Bioequivalence: The property of two drug products having the same rate and extent of absorption, producing the same therapeutic effect when administered in the same dose under similar conditions.
  • Allergic Rhinitis: An allergic inflammation of the nasal airways, commonly known as hay fever, characterized by symptoms such as sneezing, runny nose, and nasal congestion.
  • Antihistamine: A type of medication that reduces or blocks histamine, a substance produced by the body during an allergic reaction, thereby alleviating allergy symptoms.
  • Orodispersible Tablet (ODT): A tablet designed to dissolve quickly in the mouth without the need for water, making it easier to take for some patients.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Cmax: The maximum (peak) concentration of a drug observed in the blood plasma after administration.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, calculated by plotting the drug's blood levels on a graph at different time points.
  • Plasma Half-Life: The time required for the concentration of a drug in the plasma to decrease by half.
  • Crossover Study: A type of clinical trial where participants receive a sequence of different treatments over time, allowing comparison of treatments within the same individual.
  • Liposomal Formulation: A drug delivery system where the active ingredient is encapsulated in tiny lipid bubbles, potentially improving its absorption or tolerability.

References

  1. https://clinicaltrials.gov/study/NCT00533637
  2. https://clinicaltrials.gov/study/NCT00610584
  3. https://clinicaltrials.gov/study/NCT03772158
  4. https://clinicaltrials.gov/study/NCT01322282
  5. https://clinicaltrials.gov/study/NCT00863902
  6. https://clinicaltrials.gov/study/NCT00544388